<DOC>
	<DOCNO>NCT00368745</DOCNO>
	<brief_summary>GAD subject maintain stable dose alprazolam least four week meet eligibility criterion randomize receive pregabalin v match placebo simultaneously taper alprazolam 6 week . Subjects return weekly assessment safety/tolerability pregabalin v placebo well assessment anxiety benzodiazepine withdrawal symptom . Subjects successfully able discontinue alprazolam , continue 6 week treatment pregabalin v placebo ( free benzodiazepine use ) . The efficacy safety pregabalin v placebo anxiety symptom ability discontinue/remain free alprazolam compare among pregabalin placebo treat group . Hypothesis great proportion subject successful discontinue remain free benzodiazepine treat pregabalin compare subject treat placebo .</brief_summary>
	<brief_title>Efficacy Safety Pregabalin v Placebo Generalized Anxiety Disorder ( GAD ) Symptoms Subjects Discontinuing Benzodiazepine Treatment Remaining 6 Weeks Study Medication , Free From Benzodiazepine Use .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Provide write informed consent 1865 year old male female A primary lifetime diagnosis DSMIVTR ( 2000 ) GAD ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition ) Pregnant lactate woman History nonresponse alprazolam , benzodiazepine , gabapentin pregabalin give treatment anxiety indicate ( screen baseline ) Hamilton Anxiety Scale ( HAMA ) score &gt; 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>